Treating hematological malignancies with drugs inhibiting ribosome biogenesis: when and why
Abstract It is well known that chemotherapy can cure only some cancers in advanced stage, mostly those with an intact p53 pathway. Hematological cancers such as lymphoma and certain forms of leukemia are paradigmatic examples of such scenario. Recent evidence indicates that the efficacy of many of t...
Main Authors: | Enrico Derenzini, Alessandra Rossi, Davide Treré |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-05-01
|
Series: | Journal of Hematology & Oncology |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13045-018-0609-1 |
Similar Items
-
The Ribosome Biogenesis—Cancer Connection
by: Marianna Penzo, et al.
Published: (2019-01-01) -
Ribosome Biogenesis in Archaea
by: Paola Londei, et al.
Published: (2021-07-01) -
Ribosome Biogenesis and Cancer: Overview on Ribosomal Proteins
by: Annalisa Pecoraro, et al.
Published: (2021-05-01) -
From Snapshots to Flipbook—Resolving the Dynamics of Ribosome Biogenesis with Chemical Probes
by: Lisa Kofler, et al.
Published: (2020-04-01) -
Research Progress of Ribosome Biogenesis and Cancer
by: QIAN Lili, et al.
Published: (2020-05-01)